TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05757115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Skills Training
Description: Each parent will be provided with play skills training that will support them to spend effective and meaningful time with their child. While planning the educational contents, an Occupational Therapy Model suitable for the parent and the child will be used. The process will be followed by giving unique recommendations to each parent. Recommendations given based on feedback will be revised.
Study: NCT04694872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Based LSVT BIG Exercise Protocol
Description: Lee Silverman Voice Treatment-LOUD therapy is a protocol involving intensive speech therapy, which was initiated at the Lee Silverman Parkinson Center between 1987-1989 to heal hypophonia in individuals with PD. LSVT-BIG, on the other hand, is a protocol derived from LSVT-LOUD, used in neurorehabilitation, consisting of focused large-amplitude functional movements performed with great effort. Maximal Daily exercises consist of seven standard exercises. Functional component tasks, on the other hand, will be created for movements in which the patient has difficulty in daily life activities selected individually based on his complaints. In hierarchical tasks, daily life activities with difficulties will be studied with large amplitudes. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation Based Functional Balance and Mobility Exercise
Description: These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.~Exercises will get harder with each passing week and its progression will be adjusted to the patient.
Study: NCT05761730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: For a patient suffering from an irreversible pulpitis on a lower mandibular molar , 4mg of dexamethasone are administered at baseline , after inferior alveolar nerve block injection and 4mg are administered 8 hours after the first dose at office
Study: NCT06027125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation Therapy
Description: The patients in the AOT group will be required to observe the upper limb movements or functional actions in video clips and to execute what they had observed to the best of their ability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: The patients will be seated in front of a mirror box placed at their midsagittal plane to perform the movements. The affected arm of the participants was placed inside of the mirror box, and the unaffected arm was infront ofthe mirror.
Study: NCT05933161

Intervention type: DEVICE
Intervention: Freestyle Libre 3 Continuous Glucose Monitor (CGM)
Description: Subjects will be provided a Freestyle Libre 3 CGM for monitoring of blood glucose levels throughout participation in the study (approximately 3 months). CGM data will be uploaded to the LibreLink app on a weekly basis for review of glucose control and consultation with a diabetes-trained provider for any values outside of normal ranges. Adjustments to diet and medication therapy (antihyperglycemic therapy) will be made during consultations to improve episodes of hypoglycemia or severe hyperglycemia that were observed.
Study: NCT05642052

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low carb diet
Description: low carb meals will be 50% less carbs than the regular meals

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Regular diet
Description: Regular diet
Study: NCT04441034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-convulsant medications
Description: Anti-convulsants are very commonly used to treat patients with chronic pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-depressant medications
Description: Anti-depressants are very commonly used to treat patients with chronic pain.
Study: NCT04784767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
Description: SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride, USP, for injection (0.9% NaCl)
Description: Normal saline will be provided in a sterile, single-use 10 mL vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride, USP, for injection (0.9% NaCl)
Description: Normal saline will be provided in a sterile, single-use 10 mL vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride, USP, for injection (0.9% NaCl)
Description: Normal saline will be provided in a sterile, single-use 10 mL vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
Description: SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
Description: SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
Study: NCT06441890

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 80mg/m2 IV D1, 8, 15

Intervention type: DRUG
Group type: OTHER
Intervention: Nab-paclitaxel
Description: 125mg/m2 IV D1, 8, 15

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: 75mg/m2 IV D1

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Description: 8mg/kg loading, then 6mg/kg IV/SQ D1

Intervention type: DRUG
Group type: OTHER
Intervention: Pertuzumab
Description: 840 mg loading, then 420mg IV/SQ D1
Study: NCT05520541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will receive exercise-based training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Both groups will receive exercise-based training
Study: NCT06331780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual acuity
Description: VA will be measured with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Objective refraction
Description: Objective refraction will be measured using an auto-kerato-refractometer/aberrometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Objective monocular accommodation amplitude measurement
Description: Objective monocular accommodation amplitude measurements are obtained dynamically by measuring the subject's dioptric change while the participant focuses on a virtual object that moves from distance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjective monocular accommodation amplitude measurement with the Push-Up method
Description: The subjective monocular accommodation amplitude measurements are carried out by the push-up method and proceeds as follows:~* The ECP presents a near vision test card corresponding to a 0.8 (8/10) acuity line, or the smallest readable line if acuity is poor, or the smallest readable text.~* Instructions to the subject: Look at the smallest line of letters and try to see them clearly for as long as possible when I bring them closer; tell me when they start to blur and stay blurred.~* The ECP slowly brings the test card closer~* The ECP note the distance of the test card from the glasses as soon as the vision is blurred. Continue to move the test closer to check that vision remains blurred.~The amount of accommodation in this eye is equal to the proximity (= 1/distance) of the test when the blur is just perceived.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjective monocular accommodation facility measurement with the Rock method:
Description: The subjective monocular accommodation facility measurements are carried out by the Rock method and proceeds as follows:~* The ECP presents at 40cm a near vision test card corresponding to 80% of the VA.~* The ECP gives to the participant a flipper +/- 2 Dioptre~* Instructions to the subject: Look at the test and add the -2.00 D (Sphere) flipper, as soon as it's clear, return the flipper to present a +2.00 D (Sphere), as soon as it's clear, return the flipper etc... You have to do the maximum number of rotations in one minute.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CISS Questionnaire
Description: This questionnaire relating to the use of the near vision will be submitted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Difficulty assessment questionnaire
Description: After each near vision measurement, the participant should rate, on a Visual Analogic Score (0-10), the difficulty encountered, from 0: extremely easy to 10: extremely difficult. The participant may also specify the reasons for the difficulty(ies) encountered during the measurement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjective evaluation questionnaire
Description: A subjective evaluation questionnaire will be submitted to the participants at the end of the visit.
Study: NCT05743504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapy Followed by Surgery
Study: NCT05817253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portrait
Description: In the context of audit and feedback interventions, Portrait is document produced by the physician organization 'Therapeutics Initiative' that provides personalized prescribing feedback for BC family physicians (FPs). Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual physician's prescribing practice, alongside the mean and median levels of their peers (other BC physicians), a succinct review of the best-available evidence on the topic, and recommendations for future action.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portrait
Description: In the context of audit and feedback interventions, Portrait is document produced by the physician organization 'Therapeutics Initiative' that provides personalized prescribing feedback for BC family physicians (FPs). Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual physician's prescribing practice, alongside the mean and median levels of their peers (other BC physicians), a succinct review of the best-available evidence on the topic, and recommendations for future action.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portrait
Description: In the context of audit and feedback interventions, Portrait is document produced by the physician organization 'Therapeutics Initiative' that provides personalized prescribing feedback for BC family physicians (FPs). Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual physician's prescribing practice, alongside the mean and median levels of their peers (other BC physicians), a succinct review of the best-available evidence on the topic, and recommendations for future action.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutics Letter
Description: The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and help provide reference for the data presented in the Portraits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutics Letter
Description: The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and help provide reference for the data presented in the Portraits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutics Letter
Description: The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and help provide reference for the data presented in the Portraits.
Study: NCT05191069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moringa Oleifera Mouthwash
Description: 15ml of the mouthwash to be used twice daily for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mouthwash
Description: 15ml of the mouthwash to be used twice daily for 6 months
Study: NCT04978311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT) priming with task-specific training
Description: In the regimen, participants will perform MT first followed by task-specific training. After completion of MT, participants will practice task-specific training that emphasizes on restoration of essential skills for daily activities. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy priming with impairment-oriented training
Description: In the regimen, participants will perform MT first followed by impairment-oriented training. After completion of MT, participants will practice impairment-oriented training that emphasizes on restoration of movement. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control therapy
Description: The control group will receive therapeutic training equivalent in duration to the two experimental groups. The control intervention will include practice of gross/fine motor activities, training of activities of daily living, practice to increase range of motions, muscle strengthening, as well as use of adaptive or compensatory technique to alleviate functional deficits. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
Study: NCT05690945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tilesizumab
Description: Tilesizumab will be administered by IV infusion at 200mg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
Study: NCT04771585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Mask
Description: Fabric mask, no medical device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical Mask
Description: Medical face mask (personal protective equipment), CE-certified

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFP2 respirator
Description: Filtering Face Piece with no less than 94% filtering capacity, CE-certified

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFP3 respirator
Description: Filtering Face Piece with no less than 99% filtering capacity, CE-certified
Study: NCT04836663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525 tablet
Description: TQ-B3525 tablet administered orally once a day. Each cycle is 28 days.
Study: NCT06323122

Intervention type: DEVICE
Intervention: 2.0 miniplates
Description: 2.0 miniplates

Intervention type: DEVICE
Intervention: 2.3 high profile miniplates
Description: 2.3 high profile miniplates

Intervention type: DEVICE
Intervention: 3D miniplates
Description: 3D miniplates
Study: NCT05626049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Spine Provider Model
Description: Patients with LBP seeking care at intervention clinics will be offered an appointment with a DC or PT at the initial point of contact.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in this arm will receive usual care (no change to medical care).Usual care is defined as any care designated by a primary care physician (PCP).
Study: NCT04728126

Intervention type: OTHER
Intervention: Survey
Description: The questionnaire will include socio-demographic information (i.e., gender, age, job seniority) and sub-scales for measuring study variables (i.e., menopausal symptoms, social and personal resources, burnout, and work ability).~Menopausal symptoms will be assessed using the Menopause-Specific Quality of Life questionnaire.~Job burnout will be measured through OBI inventory, which consists of 16 items describing the states of emotional exhaustion and detachment - two core dimension of burnout, and were developed to meet different occupational groups.~The menopause and the quality of working environment will be assessed using the Questionnaire developed by National Health Service in England and Wales.
Study: NCT05079412

Intervention type: OTHER
Intervention: Chest ultrasound
Description: Chest ultrasound will be performed to eligiable (consented) patient after being on the respiratory support (NIV-NAVA vs NIPPV) for at least 24 hours. Both diaphragmatic function and lung ultrasound score will performed. Investigator interpreting the scans will be blind to patients type of respiratory support or clinical status.

Intervention type: OTHER
Intervention: Chest ultrasound
Description: Chest ultrasound will be performed to eligiable (consented) patient after being on the respiratory support (NIV-NAVA vs NIPPV) for at least 24 hours. Both diaphragmatic function and lung ultrasound score will performed. Investigator interpreting the scans will be blind to patients type of respiratory support or clinical status.
Study: NCT05315453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Rehabilitation
Description: 5-session Cognitive Rehabilitation intervention that can be administered over telehealth.
Study: NCT05622812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lyft Lidocaine
Description: Treatment for Jawline definition
Study: NCT04257565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wheeled Knee Walker
Description: The Wheeled Knee Walker allows total offloading of a healing limb and may diminish excessive force on the contralateral limb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual and Customary Care
Description: This group will receive usual and customary care for treatment of their diabetic foot ulcer
Study: NCT05484050

Intervention type: OTHER
Group type: OTHER
Intervention: Immunohistochemistry analysis
Description: Estimation of VEGF through Immunohistochemistry

Intervention type: OTHER
Group type: OTHER
Intervention: Immunohistochemistry analysis
Description: Estimation of VEGF through Immunohistochemistry
Study: NCT06178237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Purabond
Description: Application of Purabond to surgical field
Study: NCT05697731

Intervention type: DIAGNOSTIC_TEST
Intervention: Vidiac Score
Description: Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Vidiac Score
Description: Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
Study: NCT04692038

Intervention type: DEVICE
Intervention: Forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS
Description: During the operation, under the guidance of Augmented Reality Navigation, the bronchoscope will reach the location of the target pulmonary nodules, and the EBUS probe will be inserted through the bronchoscope working channel, and gradually approach the target nodules to obtain EBUS images. After typical EBUS images are observed and the location is confirmed, the EBUS probe will be withdrawn and biopsy forceps and puncture biopsy needle will be used to obtain samples at the target locations respectively.
Study: NCT05619978

Intervention type: OTHER
Intervention: 3L Therapy
Description: Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT

Intervention type: OTHER
Intervention: T315I
Description: Patients with chronic myeloid leukemia with T315I mutation
Study: NCT05599789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in Combination with Plinabulin and Docetaxel
Description: Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.
Study: NCT05881889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-frequency repetitive transcranial magnetic stimulation
Description: For patients in the rTMS group, we will first determine the intensity of the rTMS protocol by assessing the individual resting motor threshold (rMT). After determination of each individual's rMT, we will set rTMS intensity at 100% of the rMT and apply a single train of low-frequency rTMS over the DLPFS at 1 Hz for a total duration of 30 min (2000 pulses).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham low-frequency repetitive transcranial magnetic stimulation
Description: sham low-frequency repetitive transcranial magnetic stimulation
Study: NCT04663750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy
Description: Pars plana vitrectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12
Description: Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12
Description: Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls
Description: Subretinal injection of recombinant TPA (Alteplase, Actilyse, Boehringer Ingelheim) up to a maximum of 25 micrograms in 0.2 mls.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal 20% sulfahexafluoride (SF6) gas tamponade
Description: Intravitreal 20% sulfahexafluoride (SF6) gas tamponade.
Study: NCT05495971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaturalVue Multifocal
Description: EDOF